News for BioHarvest Sciences Inc. (CNVCF)

BioHarvest Sciences (BHST) to present at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA from August 12-14, 2025. CEO Ilan Sobel will

BioHarvest Sciences (BHST) launches VINIA DailyChews 2X Formula, targeting athletes with Informed Sport certification. The product contains 800mg of VIN

BioHarvest Sciences Inc. (BHST) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

BioHarvest Sciences Inc. (BHST) has secured a new CDMO contract to develop a plant-based fragrance compound using innovative Botanical Synthesis technology

BioHarvest Sciences leverages botanical synthesis technology for rapid growth in pharmaceuticals, nutraceuticals, cosmetics, and nutrition. Click here to read.

Revenue: Increased 47% year-over-year to $7.9 million, exceeding the $7.8 million guidance.Gross Margin: Improved by 227 basis points to 58.5%, up from 56.2% a

May 15, 2025 / 08:30PM GMTOperator Greetings, and welcome to the BioHarvest Sciences first-quarter 2025 corporate update conference call. (Operator Instructions

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of 13.33% and 1.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

BioHarvest Sciences (BHST) achieved a 47% year-over-year revenue increase in Q1 2025, reaching $7.9 million. Company's gross margin improved to 58.5%, r

BioHarvest Sciences (BHST) completes Stage 1 of its CDMO contract with a Nasdaq-listed pharmaceutical company. The Botanical Synthesis platform successf

BioHarvest Sciences Inc. (BHST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Craig-Hallum analyst Matthew Hewitt has initiated coverage of BioHarvest Sciences (BHST), assigning it a Buy rating accompanied by a price target of $15. The co

BioHarvest Sciences (BHST) will release its Q1 2025 financial results on May 15, 2025, after market close. An investor conference call and webcast will

BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BioHarvest Sciences Inc. (NASDAQ:BHST) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsIlan Sobel - CEOBar Dichter -...

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -41.67% and 1.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Revenue: $6.5 million in Q3 2024, a 101% increase year over year.Gross Margin: 57% in Q3 2024, up from 45% in the same quarter last year.Net Loss: $2.7 million

Nov 25, 2024 / 09:30PM GMTOperator Greetings, and welcome to the BioHarvest Sciences third-quarter 2024 corporate update conference call. (Operator Instructions